Raffles Medical - DBS Research 2022-11-01: Surpassing Record-Breaking Year

• Raffles Medical (SGX:BSL) released its 3Q22 Business Update, delivering another quarter of solid results as expected, in line with the strong 1H22 results. Raffles Medical's 3Q22 reported revenue growth of 6.5% y-o-y to S$199.5m while net profit surged by 62.1% y-o-y toS$38.3m. See Raffles Medical's announcement dated 31 Oct 2022. This is its first since the company moved to half-yearly reporting.
• - Read this at SGinvestors.io -
• - Read this at SGinvestors.io -
• Raffles Medical continues to expect foreign and local patients to return for treatment at its RafflesHospital, RafflesMedical, and RafflesDental branches. The potential reopening of China will also benefit RafflesChinaHealthcare.
• However, Raffles Medical highlights that slowing economic growth could dampen some high-end healthcare services, given the volatile macroeconomic environment.

Raffles Medical - Valuation & Recommendation

• Read more at SGinvestors.io.

Above is an excerpt from a report by DBS Group Research.
Clients of DBS may access the full PDF report @ https://www.dbs.com/insightsdirect/.

Read also DBS's most recent report:
2025-02-25 Raffles Medical - Strong Capital Management Signal.

Previous report by DBS:
2024-07-29 Raffles Medical - Further Normalisation Of Healthcare Services.

Price targets by 4 other brokers at Raffles Medical Target Prices.

Listing of research reports at Raffles Medical Analyst Reports.

Relevant links:
Raffles Medical Share Price History,
Raffles Medical Announcements,
Raffles Medical Dividend Payout Dates & Corporate Actions,
Raffles Medical News